Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance
title

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits

 

escrs app advert yo advert

Posters

Search Title by author or title

Results of presbyopia correction in myopic eyes with new PresbyOPA software

Poster Details

First Author: S. Bharti INDIA

Co Author(s):    B. Singh                    

Abstract Details

Purpose:

To assess the efficacy and safety of new PresbyOPA software for correction of Presbyopia in Myopic eyes.

Setting:

Bharti Eye Foundation and Hospital New Delhi, India

Methods:

30 myopic patients with myopia upto -6 D of presbyopic age between 45 and 55 years were taken for this study. Full myopic correction was done in the dominant eye.Non dominant eye was treated undercorrecting myopia by 0.75 D and Spherical aberrations of -0.3 with associated asphericity. Postoperatively all eyes were examined on day 1 and 7 thereafter on 1 3 and 6 months and binocular vision for distance and near was recorded. All the patients were asked to score their satisfaction on a score of 1 to 5 , 5 being most satisfied.

Results:

16 patients gained combination of 6/6 and N6 for distant and near vision respectively.5 patients were 6/6 N9, 4 patients 6/9 and N9, and 5 had a distant vision of 6/18 with near vision of N6. The 5 patients with a distant vision of 6/18 were retreated by lifting the flap and treating the ametropia to correct the residual myopia completely in both eyes and were given near glasses later. On the satisfaction score 16 patients gave a score of 5, 4 a score of 4, 5 a score of 3 and rest of the 5 patients a score of 1. None of the eyes lost any line of BSCVA.

Conclusions:

The PresbyOPA is safe in correcting Presbyopia in myopic eyes and complete correction is achieved in 50% patients. It is a modified monovision procedure providing extended focus and functional distance and near vision in 80 % of treated patients. The software needs to be suitably modified to achieve better results. A larger number of patients is required to assess the efficacy.

Financial Disclosure:

NONE

Back to Poster listing